Milella, M, Luchini, C, Lawlor, RT, Johns, AL, Casolino, R, Yoshino, T, Biankin, AV, Stein, LD, Park, K, Korbel, JO, Zeps, N, Rubin, MA, Marra, MA, Elemento, O, Gallinger, S, Tuveson, D, Trumper, L, Koch, R, Scarpa, A, Brennan, P, Pilarsky, C, Nikolaev, S, Yoon, SS, Lee, ES, Shibata, T, Wu, X, Wu, J, Zhan, Q, Poon, W, Al-Kuraya, KS, Eeles, R, Fitzgerald, R, Caldas, C, Abraham, J, Chang, DK (January 2022) ICGC-ARGO precision medicine: familial matters in pancreatic cancer. The Lancet Oncology, 23 (1). pp. 25-26. ISSN 1470-2045
Abstract
The International Cancer Genome Consortium–Accelerating Research in Genomic Oncology (ICGC-ARGO)1 will analyse the tumours of more than 100 000 patients with cancer during the next 10 years in a standardised way, using high-quality multiomic and clinical data (in particular outcome and treatment information) to address outstanding questions that are vital to our quest to defeat cancer (ie, the delineation of markers of prognosis, therapeutic response, and resistance). ICGC-ARGO aims to deliver a million patient-years of precision oncology knowledge, by making data available to the research community in a rapid and responsible way, to accelerate research into the causes, and control, of cancer. Here, we present the first report of a series of precision medicine-informed cases discussed by tumour boards within ICGC-ARGO programmes: two sisters, diagnosed with pancreatic ductal adenocarcinoma 7 years apart, whose disease was characterised by an uncommon clinical course; the somatic and germline profiling of these two sisters informed treatment decisions and risk management for a third sister who was not diagnosed with pancreatic ductal adenocarcinoma, but with thyroid cancer and meningioma.
Actions (login required)
 |
Administrator's edit/view item |